Bristol Myers CAR-T Trial Reports Patient Death — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Bristol Myers Squibb reported a patient death in a Phase 1 trial of its investigational CAR-T therapy for multiple sclerosis.
- The patient experienced unresolved motor symptoms, was given a potent immunosuppressant, and subsequently died from septic pneumonia.
- Bristol Myers Squibb stated the patient had been treated for other complications before receiving the CAR-T therapy, confounding the determination of the root cause.
- The event adds to existing safety concerns surrounding the expanding field of CAR-T research for autoimmune diseases.
Why it matters: For Bristol Myers Squibb and other biotechs, this death directly impacts the risk profile of a promising new application for CAR-T technology. It forces a closer examination of patient selection and complication management in early autoimmune trials, potentially slowing development timelines.
Ask SkimNews
